The CCDC167 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated by disruption of the CCDC167 gene in the NCI-H1975 human lung adenocarcinoma cell line. This product provides a mixed pool of edited cells carrying heterogeneous loss-of-function alleles, enabling functional studies of CCDC167 without clonal selection biases. The polyclonal format maintains genetic diversity while achieving effective gene knockout, making it suitable for pooled screening approaches or population-level phenotypic analyses.
NCI-H1975 is a well-characterized human non-small cell lung cancer (NSCLC) cell line derived from a female patient with lung adenocarcinoma. It harbors activating EGFR mutations (L858R and T790M), which confer sensitivity to first-generation EGFR tyrosine kinase inhibitors and resistance to later-generation inhibitors, respectively. This genetic background makes NCI-H1975 an extensively used model for studying EGFR-driven oncogenic signaling, drug resistance mechanisms, and the biology of lung adenocarcinoma.
CCDC167 encodes a predicted coiled-coil domain-containing protein whose precise molecular function remains uncharacterized. Coiled-coil domains typically mediate protein?Cprotein interactions, and bioinformatic analyses suggest a potential association with centrosomal structures. In currently available data, CCDC167 has no established upstream regulators, downstream targets, or interacting partners. Based on its domain architecture, it is hypothesized to participate in centrosome duplication or mitotic spindle organization, possibly contributing to cytoskeletal dynamics. The CRISPR-mediated knockout in this model will facilitate discovery of its cellular roles and interaction networks.
In the context of NCI-H1975, disruption of CCDC167 may reveal functions relevant to lung adenocarcinoma biology. Centrosome abnormalities are a hallmark of many cancers and can drive genomic instability and tumor progression. By eliminating CCDC167 expression in an EGFR-mutant NSCLC background, researchers can investigate how this gene influences centrosome integrity, cell cycle progression, and potentially the response to EGFR-targeted therapies. This model thus provides a platform to explore the intersection of centrosome biology and oncogenic signaling in a clinically relevant lung cancer context.
The CCDC167 Knockout NCI-H1975 Polyclonal Cells are designed for a range of downstream applications. Researchers can employ Western blotting to confirm loss of CCDC167 protein, immunofluorescence with centrosomal markers (e.g., ??-tubulin, pericentrin) to assess centrosome phenotypes, and colony formation, migration, or apoptosis assays to evaluate effects on cell behavior. RNA-sequencing of the knockout population can uncover transcriptomic changes and identify downstream pathways. Together, these assays support functional characterization of CCDC167 in lung cancer and centrosome biology. For additional information or technical support, please contact Ascent Research.
